Icahn wins second Biogen board seat - San Francisco Business Times:

http://hotesite.com/en/site-guard-and-security/page_25.html
Biogen confirmed last week the appointment of Icah n allyAlexander J. Denner. At the time, Bioge was pushing for the reelection of all ofthe company’ds four existing directors on the ballot at its annual shareholderds meeting, while Icahn was anglinf to seat four new directors. Brucr R. Ross, Biogen Idec’s chairman, said, “Wr welcome Alexander Denner and Richard Mulligam to the board and look forwared to working with them to build onBiogen Idec’sz strong track record of delivering value.” Mulligan is the Mallinckrodt Professo of Genetics at and director of the Harvard Gene Therapy Initiative, accordint to ’s Web site. Mass.
-based Biogen said shareholders rejected severalof Icahn’w other proposals, including moving the company’a incorporation from Delaware to North Dakota, a move Icahn said woulfd give more power to shareholders. Biogenn officials said it appears that stockholders also rejecteed a proposal by Icahn to limift the size of the board to 13 Biogen officials now have the power to enlargse thenow 13-member board as they see fit. Icahm is best known for unsuccessfully pushing BiogenIdec BIIB) to sell itself in 2008. Last shareholders elected the company’se nominees over the slate of investorz put upby Icahn. Biogenj Idec’s (NASDAQ: BIIB) stock was trading at $53.
17 in afternoon trading Thursday, down from the previous day’d close of $53.43 a